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Purpose: Severe neutropenia and febrile neutropenia (FN) are the major causes of morbidity, treatment
interruptions and dose reductions in patients undergoing chemotherapy. The European Oncology
Nursing Society (EONS) conducted an European survey to evaluate nurse perspectives on prevention of
infection and FN in this setting, and how much they educate their patients about this. A separate survey
explored these issues in patients receiving chemotherapy.
Methods: 217 nurse participants were identiﬁed by EONS from the membership database and 473 cancer
patients who were receiving/had received chemotherapy were identiﬁed through patient advocacy
groups. Questionnaires were completed anonymously online for both surveys.
Results: More than 90% of the nurses agreed that preventing infections including FN is extremely/very
important for a successful chemotherapy outcome and said that they, or other health professionals in
their practice, advised patients about these issues. Most (90%) indicated that they favoured giving
treatment to protect against FN and infections in chemotherapy patients at risk, rather than treating
infection after it develops, but 82% expressed concern over patient concordance with measures
employed. A substantial proportion of patients reported emergency room visits, hospitalization and/or
chemotherapy delays or changes as a result of neutropenia, infection or FN. However, only 44% said that
their infection risk was discussed with them before starting chemotherapy.
Conclusions: Our ﬁndings indicate that nurses recognise the importance of reducing the risk of infection
and FN in patients undergoing chemotherapy, as well as the need to educate patients. However, results of
the patient survey suggest a need for better patient education.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Patients undergoing myelosuppressive chemotherapy are at risk
of developing neutropenia and subsequent infections. White blood
cells (WBCs) usually reach their lowest levels 7e14 days after
chemotherapy and may take 1e2 weeks to recover spontaneously.
Febrile neutropenia (FN), generally deﬁned as fever (single oral
temperature 38.3 C or 38.0 C for >1 h) with grade 3/4 neu-
tropenia (absolute neutrophil count [ANC] < 1.0 or <0.5  109/L), is
most likely to occur during the ﬁrst cycle of chemotherapy
(Crawford et al., 1991). FN is associated with increased morbidity
and mortality risk, and often requires hospitalisation and antibiotic
treatment, thus adding considerably to the cost of treatment
(Courtney et al., 2007; Mayordomo et al., 2009; Caggiano et al.,
2005; Elting et al., 2008), as well as disrupting patients’ lives. The-NC-ND license.mortality risk was highlighted by a US study that found that almost
1 in 10 patients who were hospitalised for FN died (Kuderer et al.,
2006).
Severe neutropenia and FN are also the major cause of chemo-
therapy interruptions and dose reductions, which can potentially
compromise the efﬁcacy of cancer treatment and adversely impact
survival outcomes in curative settings (Bonadonna et al., 1995;
Bosly et al., 2007; Chirivella et al., 2009; Pettengell et al., 2008).
Accordingly, European guidelines are in place for reducing the risk
of FN (Aapro et al., 2006, 2010, 2011). A patient’s level of risk
depends on the chemotherapy regimen and patient factors such as
age and comorbidities. Prophylaxis with granulocyte colony-
stimulating factor (G-CSF) is recommended for all patients
receiving regimens with a 20% or greater risk of FN. For regimens
that are associated with a 10e20% risk of FN, individual patient
factors such as older age, advanced disease stage and FN occurrence
in a ﬁrst or previous chemotherapy cycle must also be considered
when determining the need for G-CSF support. G-CSFs are also
recommended for supporting dose-dense and dose-intense
chemotherapy, and to help maintain dose density where dose
Table 1
Nurse characteristics (n ¼ 217).
Number %
Type of Nursinga
Specialty Haematology 39 18
Oncology 115 53
Palliative Care 4 2
General Medical 31 14
Other 35 16
Specialist trainingb
Postgraduate qualiﬁcationsc 146 67
EONS TITAN course 43 20
Missing data 1 1
Nursing settinga
Part of national health system 124 57
Private practice/private facility 37 17
Other 59 27
Country
Austria 65 30
Belgium 5 2
France 17 8
Ireland 26 12
Italy 33 15
Spain 8 4
Sweden 3 1
UK 60 28
a Some respondents indicated >1 category: number of missing responses is
unclear. Percentages are calculated based on the total number of nurses.
b Sum of percentages is<100, as not all nurses had undertaken specialist training.
c In cancer nursing, palliative care or haematology.
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standardized tools have been developed for systematic assessment
of FN risk in individual patients (Aapro et al., 2010; Moore and
Fortner, 2010).
Nurses play a key role in the prevention, detection and manage-
ment of neutropenia, as well as provision of information to patients
(BuchanandCalman, 2004;Houston,1997;KearneyandFriese, 2008;
Simoens et al., 2005). EONS conducted a European survey to explore
nurse perspectives on prevention of infection and FN in patients
undergoing chemotherapy, and how much they educate their
patients about this. We also report brieﬂy the results of a parallel
survey conducted by a patient research agency (PatientView) that
aimed to evaluate these issues from a patient perspective.
Methods
Nurses’ survey
The nurse survey was developed by EONS and Amgen (Europe)
and conducted in eight European countries (Austria, Belgium,
France, Italy, Ireland, Spain, Sweden and the UK); the surveys were
translated for all participating countries. EONS contacted the
national oncology nursing societies to advertise the survey, which
was hosted on the EONS website between September and
December 2009. Nurse participants were identiﬁed by EONS from
their membership database.
Patient survey
The patient survey was conducted between September and
December 2009 by PatientView in nine countries (Austria, Belgium,
France, Germany, Italy, Ireland, Spain, Sweden and the UK). Cancer
patients who were either receiving chemotherapy, or had received
it during the past 12 months, were identiﬁed and contacted to take
part in the survey via third party patient advocacy groups. The
questions were designed to address: whether patients are aware of
the risk and consequences of neutropenic infection; and whether
patients at risk are offered prophylactic treatment to reduce neu-
tropenia, FN and infection during chemotherapy. No data were
collectedwhichwould identify the reasons for non-participation by
subjects who were contacted but chose not to participate.
Analysis
Both surveys used SurveyMonkey software and were completed
anonymously online. Results were analysed by PatientView. When
analysing responses, percentages were calculated based on the
total number of nurses or patients in the survey, rather than the
number of responses to the question (i.e patients for whom data
were missing were included in the denominator). For a small
number of questions to which more than one answer could be
given, the number of missing responses could not be readily
determined.
Results
Nurse survey
The survey included 217 nurses (Table 1), the majority (53%) of
whom were oncology nurses. Most (67%) had undertaken post-
registration qualiﬁcations in cancer nursing, palliative care or
haematology. 43 (20%) had taken the EONS TITAN (Training
Initiative on Thrombocytopenia, Anaemia and Neutropenia) course.
Only 16% indicated that they had less than 5 years’ involvement in
oncology treatment. The nurses indicated that they had an averagecaseload of 123e178 adult cancer patients per month and most
(57%) said that they cared for their patients in a national healthcare
system setting.
When asked who was primarily responsible for administering
chemotherapy in their practice, most nurses indicated that
a specialist nurse (27%), oncologist (25%) or general nurse (25%)
was responsible.
Awareness of impact of neutropenia and infections
When questioned about factors that may impact chemotherapy,
95% (n¼ 206) of nurses agreed that preventing infections including
FN is extremely/very important in order to achieve a successful
chemotherapy outcome. 96% (n ¼ 209) agreed that infection or low
WBC can delay chemotherapy (Fig. 1a). 72% (n ¼ 157) felt that
interruptions in chemotherapy may impact on the effectiveness of
treatment, while 67% (n ¼ 146) said that treatment was less likely
to be successful if there were changes in chemotherapy, such as
reducing the dosage, delaying treatment or substituting drugs. (nb.
Fig. 1 shows a total of 68% due to rounding).
Almost all of the nurses said that they, or other health profes-
sionals in their practice, discussed with patients their personal risk
of developing infection/FN (95%; n ¼ 206; Fig. 2) and how to
minimise the risk. They reported treating an average of 5e9
infections associated with FN per month, with most treating up to
10 infections per month (Fig. 3) and virtually all (95%) reported
seeing some of their patients hospitalised with fever, infection and/
or FN within the past year.
Prophylaxis and management of neutropenic infections
86% of nurses (n¼ 186) said that local and/or national guidelines
were in place for managing chemotherapy-induced neutropenia
and 78% (n ¼ 169) said that a local and/or national antibiotic policy
was in place for managing neutropenia. Most (90%; n ¼ 195) indi-
cated that in chemotherapy patients at risk they preferred to give
 Nurses (n=217)  
 Patients (n=473) 
a
b
Fig. 1. Perceptions of the impact of neutropenia, infections and changes in chemotherapy. Numbers within the bars indicate the percentage of nurses or patients who agreed or
disagreed with each statement.
Fig. 2. When do nurses or other health professionals ﬁrst discuss patients’ personal
risk of infection/febrile neutropenia? (n ¼ 217 nurses).
Fig. 3. Number of patients with infections associated with FN treated by nurses during
a typical month (n ¼ 217 nurses).
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Fig. 4. Strategies that nurses (or health professionals in their practice) ask chemotherapy patients to employ in an effort to reduce their risk of infection/febrile neutropenia (nurses
[n ¼ 217] could tick > 1 answer).
K. Leonard / European Journal of Oncology Nursing 16 (2012) 380e386 383treatment to prevent FN and infections, rather than treat an
infection once it develops.
The most common recommendations that nurses said they gave
their patients regarding how to minimise their risk of FN and
infections were to wash their hands frequently and to avoid sick
people and crowds (>80% of nurses)(Fig. 4). Almost all of the nurses
reported use of G-CSFs and/or antibiotics to reduce FN in patients
receiving myelosuppressive chemotherapy, with only 9% saying
that they did not use either (Fig. 5). When speciﬁcally asked if they
were concerned about patient concordance with FN prophylaxis
most of the nurses (82%; n¼ 179) replied that theywere ‘slightly’ to
‘extremely’ concerned.
Patient survey
473 patients (Table 2), mostly aged 40 years or older were
included in the patient survey. As these were not the same patients
being managed by the nurses in the survey, the geographical split
and type of setting differed between the two populations. A
substantial proportion of responses was missing, for example 10%
of patients failed to provide data on the number of chemotherapy
cycles they had received. 203 patients (43%) indicated that they had
received at least 6 cycles of chemotherapy, 163 (34%) said they had
received 1e5 cycles, and 58 (12%) said they did not know. Most
patients reported that an oncologist (41%; n ¼ 193), haematologist
(24%; n ¼ 112) or specialist oncology nurse (19%; n ¼ 90) was the
health professional primarily responsible for their most recent
chemotherapy.Fig. 5. Use of medication to reduce the incidence of febrile neutropenia in patients undergoin
indicated >1 category, thus sum of percentages exceeds 100. Number of missing responsesAwareness of impact of neutropenia and infections
When questioned about their awareness of neutropenia and
infections and their possible impact, approximately one-third of
patients did not answer (Figs. 1b and 6). A substantial proportion of
respondents said they did not recall (13%; n ¼ 63), or were not told
(21%; n ¼ 97) about the risk of developing FN and 15% (n ¼ 70) said
they were not told about the risk of infection. Only 39% (n ¼ 186)
said that their personal risk of developing infection was discussed
with them before starting chemotherapy. Many patients believed
that they were not always given easy-to-understand information
regarding cancer and infection (Fig. 6) and/or were unaware of the
potential impact of delays and changes in their chemotherapy
(Fig. 1b). For instance, less than 40% of patients indicated that they
had received understandable information about the medications
used to prevent infection, or increase WBC (Fig. 6).
Experience of neutropenia and infection and impact on treatment
When asked whether they had experienced a conﬁrmed infec-
tion in the last 12 months, 91 patients (19%) said yes, 198 (42%) said
no, and18 (4%) said theydid not know,while 166 (35%) did not reply.
When questioned about the impact of their ‘latest infection’ on their
chemotherapy, 75 patients (16%) said that they had to have their
chemotherapy delayed or changed as a result of neutropenia,
infection or FN. 26 patients (5%) said they had to go to the emer-
gency roomand115 (24%) said that theywerehospitalised, although
it is unclear whether some patients ticked more than 1 box.g myelosuppressive chemotherapy, as reported by nurses (n ¼ 217). Some respondents
is unknown.
Fig. 6. Level of understanding of the quality of information provided by healthcare professio
bars indicate the percentage of patients who provided a given response.
Table 2
Patient characteristics (n ¼ 473).
Number %
Sex
Male 198 42
Female 271 57
Missing data 4 1
Age range, years
< 20 26 5
20e39 33 7
40e59 211 45
60e79 194 41
Missing data 9 2
Type of cancera
Breast cancer 140 30
Lymphoma 48 10
Lung cancer 19 4
Gastrointestinal 19 4
Ovarian 8 2
Other 251 53
Chemotherapy (CT) status
Currently receiving CT 65 14
Received CT in last 12 months 89 19
CT completed >12 months ago 231 49
Don’t know 57 12
Missing data 31 7
Country
Austria 8 2
Belgium 54 11
France 39 8
Germany 67 14
Ireland 4 1
Italy 29 6
Spain 11 2
Sweden 94 20
UK 160 34
Missing data 7 1
a Sum of percentages is >100, as some patients indicated >1 category.
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Overall, less than 40% of patients reported receiving antibiotics
(107/473; 23%) or medicines that increase WBC (16%; n ¼ 76) to
prevent neutropenia and infections during their chemotherapy. 8%
of patients (n ¼ 39) said they did not know and 30% (n ¼ 140)
indicated that they had not been prescribed drugs to prevent
infection while on chemotherapy. There were only 362 replies to
this question but the number who did not reply is unclear, as
patients could tick more than 1 box. When asked which health
professional was primarily responsible for treating their latest
infection, less than 40% of patients said they were primarily treated
by an oncologist (19%; n ¼ 92) or haematologist (14%; n ¼ 65). A
small proportion (13%; n ¼ 62) indicated that they were treated by
their GP/family doctor, but again patients were able to tick more
than 1 box.
Discussion
This European nursing survey explored current perceptions and
issues relating to cancer therapy and infections associated with
neutropenia. A similar survey has subsequently been conducted in
the Netherlands and will be reported in due course. Findings
indicate that nurses recognise minimising the risk of infection and
FN as being important for achieving a successful outcome in
patients undergoing chemotherapy, as well as the need to educate
patients about these issues. When asked, a high number of nurses
(82%) expressed concern about patient concordance/compliance
with strategies aimed at preventing and managing infection and
FN.
Oncology nurses are ideally placed to play a key role in identi-
fying patients at risk of FN, as well as advising them how to reduce
the risk of infection during chemotherapy, be vigilant for signs of
infection and understand when to seek medical attention (Kearney
and Friese, 2008). Indeed, nurse-led studies have shown that
systematic identiﬁcation of patients at high risk for FN, withnals about cancer and infection, as reported by patients (n ¼ 473). Numbers within the
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reduce chemotherapy dose delays and reductions and FN-related
hospitalisations (Moore and Fortner, 2010). A signiﬁcant propor-
tion of the nurses in our survey (20%) had completed the EONS
TITAN course (http://www.cancernurse.eu). This programme was
adapted for European nurses from the well-established and
successful US programme, ATAQ (Appropriate Treatment Assures
Quality). Specialist training has been shown to improve nurse
conﬁdence (Aerts et al., 2010; Atkinson and Tawse, 2007; Verity
et al., 2008). An earlier learning needs assessment conducted by
EONS found that oncology nurses were eager to develop their
knowledge and accept more responsibility for educating patients
about haematological toxicities and their management (Foubert
et al., 2005). The objectives of TITAN are to provide nurses with
current data on the impact of haematological toxicities on clinical
outcomes and quality of life; help nurses to identify patients at risk;
teach innovative and evidence-based methods for educating
patients, families and nursing staff and encourage participants to
actively disseminate what they learn from TITAN (Ahlberg et al.,
2005; Brenner, 2005). The TITAN Programme has been tailored to
different countries and has now been delivered across Europe. In
some countries it is delivered by nurses and in others by physicians.
The patient survey ‘Preventing Febrile Neutropenia-Staying on
Trackwith Chemotherapy’ has a number of limitations but has been
included in this report because the ﬁndings were, nevertheless, of
interest. The survey relied on individual recall, with a long timelag
between treatment and survey participation in some instances, as
patients who had completed chemotherapy more than 12 months
previously were included. There may have been some selection
bias, as reasons for non-participation were not recorded. Respon-
dents completed the survey online and would therefore need to be
computer-literate. There were many missing responses, the
number of respondents could not be determined for some ques-
tions, and moreover, some of the answers that were given seemed
incongruous. It is not clear whether all patients were at risk of
developing neutropenia or were receiving curative chemotherapy
and some patients received less than 6 cycles of chemotherapy.
Only 44% of respondents said that their infection risk was discussed
with them before starting chemotherapy and many indicated that
they did not knowwhat treatment theywere receiving tominimise
the risk. It is evident that a substantial proportion of patients did
develop infection, although the actual incidence was undoubtedly
underestimated, with a large disparity between the number of
patients indicating that they had had a conﬁrmed infection in the
last 12 months (n ¼ 91) and the number who replied to the ques-
tions about their latest infection (n ¼ 203 and 204). Of the latter
group, the majority reported having their chemotherapy delayed or
changed as a result of neutropenia, infection or FN (37%), going to
the emergency room (13%) and/or being hospitalised (57%). The
type and severity of infection was not recorded.
While only very tentative conclusions can be drawn from the
patient survey, the results suggest that many patients do not
understand, or are unaware of the risk of, developing neutropenia,
FN or infection and how this can impact on delivery of their
chemotherapy and the treatment outcome. They may be given
a great deal of complex information regarding their diagnosis,
treatment and prognosis, including information on other toxicities
such as hair loss. Thus, the importance of fever and infectionmay be
‘lost in the noise’, if not given sufﬁcient emphasis.
Differing treatment settings and countries are likely to account
for some of the observed differences in perceptions between the
nurse and patient populations. As few details regarding treatment
settings were collected, it is not known whether the surveyed
nurses and patients were in predominantly inpatient, outpatient,
community or university hospital settings. For both parts of thesurvey, results were pooled for the different countries, although
nursing practices and patient education may differ according to
locale. Numbers were low for some countries (Tables 1 and 2), with
much of the data (28% of nurses and 34% of patients) coming from
the UK, Austria (30% of nurses) and Sweden (20% of patients).
Eastern European countries were not represented. Ideally, one
would survey the same patients who were being treated by the
nurses in the survey and this would allow gaps in knowledge to be
clearly identiﬁed.
Conclusions/recommendations
Our results suggest that theremay be a need for improvement in
a number of areas of oncology care, including:
(i) Communication between patients and healthcare profes-
sionals regarding the risk of chemotherapy-induced neu-
tropenia/FN. Patients need to receive understandable and
timely information although this may be hampered by lack of
time and nurse shortages (Aerts et al., 2010; Royal College of
Nursing, 2011).
(ii) Education/links to information for healthcare professionals
looking after patients in the community.
(iii) Provision of effective prophylaxis against neutropenia
according to current guidelines (Aapro et al., 2011).
(iv) Ensuring patient concordance with prophylaxis.
(v) Access to oncologists/haematologists for patients who develop
infection. This may be difﬁcult for patients who are treated in
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